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Ascorbate is a co-factor for the hydroxylases that regulate the transcription factor hypoxia-
inducible factor (HIF)-1, which provides cancer cells with a metabolic and survival advantage
in the hypoxic environment of solid tumors. However, whether ascorbate affects tumor
development is a highly debated issue. We aimed to determine whether tumor ascorbate
was associated with HIF-1 activation and patient disease-free survival. In this study, we
undertook a retrospective observational analysis of tissue-banked tumor and paired normal
tissue from 49 colorectal cancer patients, measuring ascorbate levels, HIF-1α and its down-
stream gene products BNIP3, and vascular endothelial cell growth factor (VEGF). Patient
survival was monitored for the first 6 years after surgery. We found that ascorbate levels
were lower in tumor tissue compared to normal tissue (p<0.001) but overall levels varied
considerably. HIF-1α, VEGF, and BNIP3 were elevated in tumor samples (p<0.01). There
was an inverse relationship between tumor ascorbate content and HIF-1 pathway activation
(p=0.002) and tumor size (p=0.018). Higher tumor ascorbate content was associated with
significantly improved disease-free survival in the first 6 years after surgery (p=0.006), with
141–1,094 additional disease-free days. This was independent of tumor grade and stage.
Survival advantage was associated with the amount of ascorbate in the tumor, but not with
the amount in adjacent normal tissue. Our results demonstrate that higher tumor ascor-
bate content is associated with decreased HIF-1 activation, most likely due to the co-factor
activity of ascorbate for the regulatory HIF hydroxylases. Our findings support the need
for future studies to determine whether raising tumor ascorbate is possible with clinical
intervention and whether this results in modification of hydroxylase-dependent pathways
in the tumor.
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INTRODUCTION
Hypoxia-inducible factor (HIF)-1 is a transcription factor that
up-regulates the expression of hundreds of genes that enable the
successful adaptation of solid tumors to the metabolic challenges
of a hypoxic microenvironment (1, 2). Increased HIF-1 has been
linked to poor patient prognosis (3–6) and is implicated in radio-
and chemo-resistance (4, 7) and metastasis (8, 9). Consequently,
there is great interest in potential inhibitors of HIF-1 for use in
cancer therapy (10, 11).
Hypoxia-inducible factor-1 activity is controlled by post-
translational hydroxylation of the α subunit: hydroxylation of
prolines 402 and 564 by prolyl-hydroxylases (PHDs) targets
HIF-1α for rapid proteasomal degradation, and hydroxylation
of asparagine 803 by factor inhibiting HIF (FIH) prevents
HIF-1 co-activation with p300 (12). Thus, optimal PHD and
FIH activity directly inhibits HIF-1 transcriptional activity. The
HIF hydroxylases are members of the 2-oxoglutarate-dependent
dioxygenase family (13) that also includes the collagen prolyl-4-
hydroxylase (C-P4H) and jumonji histone demethylases (JmjC
family) (14). These enzymes have a non-heme iron in the cat-
alytic site and they require oxygen and 2-oxoglutarate as sub-
strates (15) and ascorbate as a co-factor (12, 13). The absence
of ascorbate compromises HIF-hydroxylase activity and leads to
increased activation of HIF-1 in both cancer and primary cells
in vitro (16–18).
The amount of intracellular ascorbate required for optimal
HIF-hydroxylase activity is reflected in the Km values for ascor-
bate, being 140–180µM for the PHDs and 260µM for FIH (12).
Normally, adequate levels are maintained by active transport from
the plasma and most tissues achieve low millimolar intracellular
concentrations (19, 20). However, if supply is limited either by
low plasma levels or due to poor vascular delivery, tissue ascorbate
levels can drop dramatically (21). Therefore, in order to maintain
ascorbate saturation and optimal HIF-hydroxylase activity, cells
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require good accessibility and adequate circulating levels, both of
which may be compromised in patients with solid tumors (22, 23).
Hence we propose that if tumor ascorbate is limiting, the HIF
hydroxylases could be inhibited and the hypoxic response exac-
erbated. Improved supply of ascorbate could therefore provide
an anti-cancer mechanism by optimizing HIF-hydroxylase activ-
ity and down-regulating HIF-1. There is some evidence that this
can occur. In mouse models, ascorbate supplementation reduces
tumor growth in a HIF-1-dependent manner (24, 25). We also
reported an association between low ascorbate levels and high
HIF-1 activation in human endometrial tumors (26), the first
demonstration of an association between ascorbate and HIF-1 in
a human tumor. We now report the analysis of surgically removed
human colorectal cancer tissue.
Colorectal cancer is prevalent worldwide, with a high mor-
tality rate (27) and is known to have increased HIF-1 expres-
sion that is associated with poor outcome (3, 28, 29). We have
measured ascorbate levels, HIF-1α protein levels, and three HIF-
1-controlled pro-survival target gene products; Bcl-2/adenovirus
E1B 19 kDa interacting protein 3 (BNIP3), glucose transporter 1
(GLUT-1), and vascular endothelial cell growth factor (VEGF), in
tumor and patient-matched adjacent normal tissue and compared
these results to clinico-pathological data. We have complete 6-year
follow-up data for this cohort of patients and have analyzed the
impact of tumor ascorbate and HIF-1 activation on disease-free
and overall survival.
MATERIALS AND METHODS
HUMAN ETHICS, COLORECTAL CANCER PATIENTS, AND FOLLOW-UP
Colorectal tumor and paired normal tissue samples (n= 49
patients with n= 50 pairs of samples) were obtained from the
Cancer Society Tissue Bank, Christchurch (CSTBC). The sam-
ples were selected at random to represent a spread of male and
female patients (42 and 58%, respectively), with a variety of
tumor grades, stages, and sizes (Table 1). Donors gave written
consent allowing research on their samples and ethical approval
was granted by the Upper South B Regional Ethics Committee,
New Zealand.
Colorectal cancer patients who had gifted tissue between
September 1998 and July 2008 were investigated. All colorec-
tal patients treated at Christchurch hospital are offered standard
care: post-operative adjuvant chemotherapy (intravenous weekly
5-fluorouracil with leucovorin, capecitabine, or an oxaliplatin
combination) for patients with nodes involved and also node-
negative patients with adverse features. Patients are followed up
with 6-monthly clinical assessment and blood carcinoembryonic
antigen, with an annual and then 3-yearly colonoscopy. Follow-
up was documented until December 2012. Stage 4 patients with
metastasis on presentation were excluded (n= 3), as their disease
was considered as already progressed, and another patient (n= 1)
was excluded as metastasis was discovered during surgery. In addi-
tion, patients who did not recover from surgery (i.e., died within
10 days of surgery) were excluded (n= 2). Two tumor samples
were obtained from a single patient who presented with two inde-
pendent primary tumors 4 years apart – survival data was applied
to the first tumor surgery only, leaving 43 patients to be included
in survival analysis.
Table 1 | Clinical features of the colorectal cancer tissue sample set.
Clinical parameter n (%)
GRADE
1 (Well differentiated) 9 (18)
2 (Moderately differentiated) 20 (40)
3 (Poorly differentiated) 21 (42)
AJCC STAGE
1 7 (14)
2A 12 (24)
2B 6 (12)
3A 1 (2)
3B 11 (22)
3C 10 (20)
4 3 (6)
SPECIMEN POSITION
Right ascending colon 17 (34)
Left descending colon 5 (10)
Transverse colon 1 (2)
Cecum 3 (6)
Sigmoid colon 9 (18)
Rectum 1 (2)
ND 14 (28)
TUMOR SIZE
≤50 mm 32 (64)
>50 mm 17 (34)
ND 1 (2)
NECROSIS
No 23 (46)
Yes 7 (14)
ND 20 (40)
LYMPH/VASCULAR INVASION
No 32 (64)
Yes 17 (34)
ND 1 (2)
AJCC, American Joint Committee on Cancer; ND, no data.
TISSUE PREPARATION
All colorectal tumor tissues were obtained as part of surgical resec-
tion with both tumor and normal tissue (from uninvolved mucosa
≥100 mm from the tumor edge) collected. Tissue samples were
flash-frozen in liquid N2 within an hour of collection and stored
at −80°C. Frozen samples were ground to a fine powder in liq-
uid nitrogen, the collected tissue weighed, and 10 mM phosphate
buffer (pH 7.4) added to make a homogenous suspension that was
used to measure DNA (cellularity), tissue ascorbate content, and
HIF-1α protein and gene product expression (26).
Hypoxia-inducible factor-1α was detected with mouse anti-
human HIF-1α (1:1,000) (BD Biosciences, San Jose, CA, USA);
BNIP3 with goat anti-human BNIP3 (1:1,000) (R&D Systems,
Minneapolis, MN, USA); and GLUT-1 with rabbit anti-human
GLUT-1 (1:3,000) (Abcam, New Zealand). Anti-β-actin primary
antibody (1:10,000), horseradish peroxidase (HRP)-conjugated
goat anti-mouse (1:2,500), rabbit anti-goat (1:20,000), and goat
anti-rabbit (1:20,0000) were from Sigma Aldrich, St Louis, MO,
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USA. Protein detection was with ECL™ Plus detection reagent
(GE Healthcare/Amersham Biosciences, Buckinghamshire, UK).
Human VEGF protein was measured using a DuoSet ELISA from
R&D Systems. Complete Mini protease inhibitor cocktail was from
Roche Diagnostics (Mannheim, Germany).
DNA CONTENT
Cell content was detected by monitoring DNA content of the tis-
sue homogenate, diluted 1:25 and disrupted in 10 mM phosphate
buffer, pH 7.4. Propidium iodide was added (1 mg/ml; 10 min, RT)
and fluorescence measured at 544–590 nm, relative to a standard
curve of purified calf thymus DNA.
ASCORBATE MEASUREMENT
Ascorbate was extracted from the tissue homogenate by imme-
diately adding a 1:1 volume of 0.54 M perchloric acid contain-
ing 50 mM diethylenetriaminepentaacetic acid (DTPA). The pro-
tein was pelleted and the supernatant analyzed by reverse-phase
high performance liquid chromatography with electro-chemical
detection (HPLC–ECD; mobile phase: 80 mM sodium acetate,
pH 4.8, with 0.54 mM DTPA as previously described) (30). A
fresh standard curve of sodium-l-ascorbate was prepared for
each run.
WESTERN BLOTTING
Hypoxia-inducible factor-1α, GLUT-1, BNIP3, and β-actin pro-
tein levels were measured by Western blotting. Homogenates were
standardized to 15µg DNA per 100µl sample buffer (60 mM Tris
pH 4.8, 2% SDS, 20% glycerol, 0.1 M DTT, Complete Mini protease
inhibitor cocktail, and bromophenol blue) (26). After detection of
the primary target, the membranes were re-probed for β-actin as
a loading control. Images were captured using a ChemiDoc XRS
gel documentation system (Bio-Rad Laboratories, Hercules, CA,
USA) and densitometry performed using Quantity One® software
(Bio-Rad). Each protein was quantified relative to β-actin, and to
normalize the signal between blots, quantified relative to a positive
control for each protein of previously analyzed endometrial tumor
tissue total protein (26).
VEGF ELISA
Vascular endothelial cell growth factor protein levels were mea-
sured in the tissue homogenate, diluted 1:25 in 10 mM phosphate
buffer, pH 7.4, by a commercial ELISA (R&D Systems) according
to the manufacturer’s instructions.
STATISTICAL ANALYSES
Data were analyzed using SPSS 19.0 with the alpha level set to
0.05. The Kolmogorov–Smirnov test determined the distribution
of each variable. All data was non-parametric except for the ascor-
bate levels. For differences between normal and tumor data, the
Mann–Whitney test was used and for differences between tumor
grades, the Wilcoxon signed ranks test was used. Correlations
were determined using Spearman’s correlation coefficient. Linear
regression analysis was also used in tumor size and HIF-1 path-
way score analyses. The Student’s t -test determined differences
in ascorbate levels. Survival analyses were performed in R 2.14
(Vienna, Austria).
RESULTS
HIF-1α AND TARGET GENE PROTEIN LEVELS
Hypoxia-inducible factor-1α protein was detected in 29 of 50
tumors (58%) and in 4 of 50 normal tissue samples (8%). We
determined significantly higher levels of HIF-1α protein in tumor
compared to normal tissue (p< 0.001; Figure 1A). BNIP3 was
detected in 38 of 50 tumors (76%) and 21 of 50 normal tis-
sues (42%) and was higher in tumor compared to normal tissue
(p= 0.004; Figure 1B). GLUT-1 was detected in 36 of 50 tumors
(72%) and 34 of 50 normal tissues (68%) with no difference in
levels between normal and tumor samples (Figure 1C). VEGF
protein was detectable in 50 of 50 tumors (100%) and 49 of 50
normal tissues (98%) with higher levels in tumor than normal
tissue (p< 0.001; Figure 1D).
As ascorbate can affect HIF-1α protein levels and transcrip-
tional activity, the values for HIF-1α protein and expression of
BNIP3, GLUT-1, and VEGF were combined to assess the activation
of the HIF-1 pathway in relation to ascorbate content. The level of
each protein was normalized relative to the maximum expression
and the mean of all four values for each sample was assigned as
the “HIF-1 pathway score” (26). This was verified by correlation
with the individual protein levels (Table 2). The HIF-1 pathway
score was significantly higher in tumor compared to normal tissue
(Figure 1E; p< 0.001).
ASCORBATE CONTENT IN TUMOR AND NORMAL TISSUE SAMPLES
Tissue ascorbate content was measured using HPLC–ECD
(Figure 2). The stability of ascorbate in banked tissue as well as our
protocol for ascorbate extraction has previously been verified, with
no loss from intact tissue at room temperature for up to 5 h, nor
upon long-term storage at−80°C (26). Tumor tissue had increased
DNA content compared with normal tissues (4.50± 1.49 and
2.26± 1.04µg DNA per milligram wet weight± SD, respectively;
p< 0.001), consistent with increased cell density of tumor tissue.
As it is the intracellular level of ascorbate that is relevant to the
control of HIF-1, the ascorbate measurements were standardized
against the DNA content and expressed as nanomoles ascorbate
per microgram DNA. There was a strong correlation between DNA
content and absolute ascorbate levels (mg per 100 g wet weight)
in both normal and tumor tissues (Spearman’s rho= 0.547 and
0.482, respectively; p< 0.001), suggesting that most of the ascor-
bate in the tissues was indeed intracellular. Furthermore, the
DNA content did not increase with tumor grade, indicating that
aneuploidy is unlikely to confound the measurement.
Two parameters were measured; (1) absolute ascorbate mea-
surements in the tumor tissue, that reflect plasma supply, vascular
delivery, and cellular uptake, and (2) the ability of the tumor to
accumulate ascorbate relative to the surrounding tissue (shown as
a ratio of tumor: normal tissue), which allows for correction for
the individual patient’s ascorbate status and most likely reflects
vascular delivery.
When measuring the absolute tumor ascorbate levels, signif-
icantly lower levels were found to be present than in normal
tissue (p< 0.001; Figure 2A). When expressed relative to normal
tissue, the median tumor ascorbate ratio was 0.70 (p= 0.001).
This difference was attributable to the high grade tumors with
the median tumor: normal ascorbate ratios being 0.910, 0.695,
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FIGURE 1 | HIF-1 activation in normal and tumor colorectal tissue
samples. Representative Western blots from normal and tumor tissue
samples are shown for HIF-1α (A), BNIP3 (B), and GLUT-1 (C), together with
boxplots of densitometry results from all samples normalized to the same
positive control for each protein and to β-actin loading control. VEGF protein
levels were measured by ELISA (D). All proteins except GLUT-1 were elevated
in tumor compared to normal tissue. HIF-1 pathway score (E), was
determined for each sample from the combined analysis of all four protein
levels, normalized as percent maximum expression and the mean taken. This
measure was significantly higher in tumor compared to normal tissue. For all
measures, n=50 cases with normal and tumor tissue samples for each;
significance determined by Mann–Whitney test.
and 0.610 for grade 1, 2, and 3 tumors, respectively (Figure 2B).
This difference was not due to variations in the cellularity of
the three tumor grades, as each had the same DNA content
[4.95± 1.50, 4.14± 1.56, and 4.65± 1.40µg DNA per milligram
wet weight (means± SD), for grades 1, 2, and 3, respectively].
These results indicate that high grade colorectal tumor tissue has
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Table 2 | Spearman’s correlations between colorectal tumor tissue ascorbate content, HIF-1 activation markers, and tumor size.
Ascorbate
content
(nmol/µg DNA)
Tumor: normal
ascorbate ratio
HIF-1α
band
density
GLUT-1
band
density
BNIP3
band
density
VEGF
(pg/mg
tissue)
HIF-1
pathway
score
Tumor
size
(mm)
Ascorbate content
(nmol/µg DNA)
r 0.651a 0.006 −0.223 −0.302b −0.321b −0.445a −0.256
p 0.000 0.970 0.120 0.033 0.023 0.001 0.076
Tumor:normal
ascorbate ratio
r 0.651a 0.112 −0.357b −0.134 −0.305b −0.364a −0.112
p 0.000 0.437 0.011 0.354 0.031 0.009 0.445
HIF-1α band
density
r 0.006 0.112 0.026 0.135 0.153 0.284b 0.127
p 0.970 0.437 0.856 0.351 0.288 0.046 0.385
GLUT-1 band
density
r −0.223 −0.357b 0.026 0.058 0.012 0.284b −0.069
p 0.120 0.011 0.856 0.691 0.932 0.045 0.637
BNIP3 band
density
r −0.302b −0.134 0.135 0.058 0.124 0.781a 0.083
p 0.033 0.354 0.351 0.691 0.393 0.000 0.572
VEGF (pg/mg
tissue)
r −0.321b −0.305b 0.153 0.012 0.124 0.493a 0.172
p 0.023 0.031 0.288 0.932 0.393 0.000 0.236
HIF-1 pathway
score
r −0.445a 0.364a 0.284b 0.284b 0.781a 0.493a 0.057
p 0.001 0.009 0.046 0.045 0.000 0.000 0.695
Tumor size (mm) r −0.256 −0.112 0.127 −0.069 0.083 0.172 0.057
p 0.076 0.445 0.385 0.637 0.572 0.236 0.695
For all analyses n=50, except for tumor size, where n=49. Significant associations are shown in bold font.
aCorrelation is significant at the 0.01 level (two-tailed).
bCorrelation is significant at the 0.05 level (two-tailed).
a reduced capacity to accumulate ascorbate compared to sur-
rounding normal tissue, and also compared to low grade tumor
tissue.
ASCORBATE AND HIF-1 ACTIVATION MARKERS
Tumor ascorbate content and the HIF-1 pathway score were evenly
distributed for all tumor grades (Figure 2C), with samples with
high and low absolute ascorbate content in each grade. Analy-
sis of the data showed a strong inverse relationship between the
HIF-1 pathway score and tumor ascorbate content (r =−0.445,
p= 0.001; Table 2; Figure 2C). VEGF and BNIP3 protein levels
were also inversely correlated to tumor ascorbate content (Table 2).
The ascorbate ratio (tumor:normal) was inversely correlated to
VEGF and GLUT-1 protein levels, as well as to the overall HIF-1
pathway score (Table 2).
When samples were separated according to the median ascor-
bate content (0.13 nmol/µg DNA), the ascorbate-replete tumors
had significantly lower HIF-1 pathway scores than low ascorbate
tumors (Figure 2D; p= 0.005).
There was an association between tumor size and ascorbate
content, with larger tumors having less ascorbate (Figure 3A). In
contrast, there was no association between normal tissue ascor-
bate levels and tumor size (r = 0.024, p= 0.292). We did not find
any associations between tumor ascorbate levels and the HIF-1
pathways score with AJCC stage (p= 0.781) or lymph/vascular
invasion status (p= 0.817) of the tumors. There was a tendency
for tumors positive for necrosis to have less ascorbate, with data
available for 30 out of 50 tumors (Figure 3B; p= 0.067).
COLORECTAL CANCER PATIENT SURVIVAL
We were able to map 6-year post-surgery survival data for 43 of the
49 patients. Excluded from the analysis were four patients who had
metastatic disease at time of surgery and to whom the disease-free
status does not apply, and two patients who died of complica-
tions within days of surgery. The cohort was divided into “high”
(n= 22) and “low” (n= 21) categories based on the median tissue
ascorbate content or median tumor:normal ratio.
The results indicate a distinct disease-free survival advantage
for those patients with higher tumor ascorbate levels (p= 0.006;
Figure 4). Although the sample size was too small to include
covariates in the analysis, the “high” and “low” groups contained
similar proportions of tumor grades and stages, indicating that
there is no bias by disease severity (Figure 4). In contrast with this,
the ascorbate content of normal tissue was not related to patient
outcome (p= 0.614). The results were similar whether ascorbate
content was measured as milligram per 100 g of tissue or nanomole
per microgram DNA (Table 3). In addition, inclusion of the six
excluded patients did not change the interpretation of the results
with similar findings observed when analyses were carried out on
n= 49 (Table 3).
Patients with high ascorbate in their tumors relative to nor-
mal tissue had between 141 and 1,094 additional disease-free days
in the first 6 years after surgery (p= 0.011), with the range likely
reflecting the small sample size (n= 43). Assessment of patient
overall survival did not show any associations or trends with
respect to ascorbate: this is likely to be due to median survival not
being reached, to the relatively advanced average age (78 years) and
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FIGURE 2 |Tumor ascorbate analysis and HIF-1 pathway activation
in colorectal tumor samples. (A)Tissue ascorbate levels are
significantly lower in tumour compared to normal tissue samples as
measured by paired student’s t -test (n=50 normal and tumour
samples, data represent mean±SEM). (B)Tumour: normal tissue
ascorbate ratio by tumour grade. Boxplot of the ratio of ascorbate in
tumour relative to matching normal tissue, showing high grade
tumours have significantly less ascorbate than surrounding normal
tissue from the same patient. †p<0.01, normal vs. tumour by Wilcoxon
signed ranks test; n=9, 20, and 21 for grade 1, 2, and 3, respectively.
(C) Scatterplot showing tumor tissue ascorbate levels are inversely
related to the HIF-1 pathway score (linear regression analysis). Grade 1,
© (n=9), grade 2,  (n=20), and grade 3, N (n=21). (D) Boxplot
showing division of tumor samples according to the median ascorbate
level, with ascorbate-deficient tumors (ascorbate <0.13 nmol/µg DNA;
n=25) having significantly higher HIF-1 pathway scores than
ascorbate-replete tumors (ascorbate >0.13 nmol/µg DNA; n= 25) as
determined by Mann–Whitney test.
because we did not have cause of death information and could not
exclude other confounding factors.
DISCUSSION
Whether ascorbate is of benefit to cancer patients has long been
argued, with little information being available to substantiate
claims of efficacy. Recent information from both human and ani-
mal studies is highly suggestive of a clinical benefit, and several
mechanisms of action have been proposed (31–33). To our knowl-
edge,our retrospective analysis of colorectal cancer is the first study
to measure patient outcome in relation to tumor ascorbate con-
tent and to show that this is associated with activation of HIF-1,
a known driver of tumor growth and metastasis. We found that
the ascorbate content of tumor samples is associated with HIF-
1 activation, tumor characteristics, and metastases. Disease-free
survival was associated with the ascorbate level in the tumor, but
not in normal tissue, suggesting that the most important determi-
nant is the amount of ascorbate in the tumor and not the patient’s
overall ascorbate status.
We previously showed that decreased ascorbate levels are asso-
ciated with high HIF-1 activation in endometrial cancer (26), but
patient survival data was not available. The current study has
corroborated our previous findings in endometrial cancer, making
an important advance in determining whether sub-optimal tumor
ascorbate leads to over-activation of HIF-1. It has also indicated
that ascorbate levels influence tumor progression.
Our findings are supported by in vitro studies showing that
ascorbate supplementation can inhibit HIF-1 activation in cancer
or primary cells (16, 17, 34, 35). Furthermore, in vivo observa-
tions showed that increased ascorbate reduced HIF-1-dependent
tumor genesis in wild-type mice (25). Enhanced tumor growth
and metastasis has been also shown inGulo−/− ascorbate-deficient
mice compared to ascorbate-supplemented mice (36, 37), and
this was associated with increased HIF-1 target gene expression
(MMP9 and VEGF) (37).
Our previous study with endometrial cancer samples was
the first measurement of ascorbate levels and HIF-1 activation
in human cancer. The current study, with the acquisition of
patient survival data, is consistent with the hypothesis that low
tumor ascorbate content may lead to HIF-1-dependent tumor
progression.
The use of ascorbate to treat cancer is contentious, with lit-
tle clinical evidence to support the practice. Despite this, the
administration of high-dose intravenous ascorbate to cancer
Frontiers in Oncology | Cancer Molecular Targets and Therapeutics February 2014 | Volume 4 | Article 10 | 6
Kuiper et al. Tumor ascorbate, HIF-1 and survival
FIGURE 3 |Tumor ascorbate levels in relation to tumor size and
necrosis. (A) Scatterplot showing an inverse relationship between tumor
ascorbate levels and tumor size (linear regression analysis). Grade 1,©
(n=9), grade 2,  (n=20), and grade 3, N (n=21). (B)Tumors positive for
necrosis (n=7) tended to have lower ascorbate levels than tumors with no
detectable necrosis (n=23) as determined by unpaired Student’s t -test.
Data represent mean±SEM.
patients is widespread (38). Pharmacokinetic studies have demon-
strated more than 100-fold higher plasma ascorbate levels after
intravenous than after oral administration (39). This increased
availability may explain some of the discrepancies between the
definitive clinical trial in the 1980s (40) using oral ascorbate to
treat cancer and earlier studies by Cameron and Pauling using both
oral and intravenous ascorbate (41, 42). Because of new under-
standing of the pharmacokinetics, possible roles for ascorbate in
cancer are now being investigated, spurring the growing body of
pre-clinical evidence demonstrating the effectiveness of ascorbate
against tumor cell growth and survival (16, 25, 31, 33, 43–46).
We found that tumor tissue contained up to 40% less ascor-
bate than adjacent normal tissue. The reasons for this are unclear;
however it is known that accumulation of intracellular ascorbate
is influenced by expression and activity of the active transporter
SVCT2 (47) and availability of ascorbate in the extracellular milieu.
The latter largely reflects the delivery of ascorbate from plasma to
Tumor ssue ascorbate 
(nmol/µg DNA)
n AJCC stage
1 2 3 4
< 0.133 22 3 8 11 0
> 0.133 21 3 9 9 0
Grade
1 2 3
< 0.133 22 3 10 9
> 0.133 21 4 8 9
FIGURE 4 | Disease-free survival of colorectal cancer patients
according to ascorbate. Each tumor ascorbate parameter was divided into
“high” (n=22, solid lines) and “low” (n= 21, dotted lines) categories based
on the median value. The proportion of disease-free patients was plotted
over time since their tumor resection surgery. Each step down on the
figures represents a patient whose cancer has progressed, and each tick
mark represents cessation of follow-up of a patient. Low tumor tissue
ascorbate content is significantly associated with shorter disease-free
survival (p=0.006; median=0.133 nmol/µg DNA).
the tissues and this depends on both the plasma levels as well as
an effective vascular network. These can both be affected in cancer
patients who reportedly have decreased circulating ascorbate (22,
23) and whose tumors have dysfunctional vasculature (48). Poorly
functioning tumor vasculature results in regions of hypoxia and
it is highly plausible that this would also compromise ascorbate
supply to tumor cells and also to the many other cell types (such
as endothelial cells, fibroblasts, and immune cells) that make up
the complex tumor microenvironment.
Our results indicate that it is the absolute amount of ascorbate
in the tumor tissue (and which was independent of grade and
stage), rather than the patient’s overall ascorbate status, that was
associated with disease-free survival. This suggests that increasing
tumor tissue ascorbate levels may be beneficial.
Delivery of ascorbate to tumor tissue may be a limiting fac-
tor for its therapeutic value. It is unknown what plasma con-
centrations are required for adequate tumor tissue penetration
and whether this can be achieved through dietary intake or
whether intravenous administration may be necessary. Maximum
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Table 3 | Patient 6-year disease-free survival percentages according to tumor and normal tissue ascorbate measurements.
Median value <Median (%) >Median (%) 95% CI p
ASCORBATEAS nmol/µg DNA (n=43)
Tumor tissue 0.133 33.5 72.4 11.3 66.6 0.006*
Normal tissue 0.205 57.3 49.6 −37.5 22.2 0.614
Tumor:normal ratio 0.709 39.7 67.0 −1.6 56.3 0.064
ASCORBATEAS nmol/µg DNA (n=49)
Tumor tissue 0.132 30.8 63.8 6.2 59.7 0.016*
Normal tissue 0.212 56.7 39.6 −45.1 10.8 0.230
Tumor: normal ratio 0.695 29.2 66.6 11.1 63.7 0.005*
ASCORBATEAS mg/100gTISSUE (n=43)
Tumor tissue 12.2 38.3 67.9 1.0 58.2 0.043*
Normal tissue 8.0 46.5 59.1 −17.4 42.5 0.410
Tumor: normal ratio 1.50 40.9 66.5 −3.3 54.5 0.083
ASCORBATEAS mg/100gTISSUE (n=49)
Tumor tissue 11.9 35.2 59.5 −3.3 51.9 0.084
Normal tissue 8.2 46.9 48.0 −27.4 29.7 0.938
Tumor: normal ratio 1.46 29.2 66.3 10.8 63.6 0.006*
Estimates from log-rank tests (dichotomous at the median level); p, significance (*). Bold font indicates a significant association.
plasma ascorbate levels reach only ~100µM through gastrointesti-
nal absorption, whereas intravenous administration can result in
plasma concentrations above 10 mM (39). Pharmacokinetic data
on ascorbate in tumor tissues following administration would be
particularly valuable in order to determine the optimal dose regi-
men to achieve cellular levels optimal for HIF-hydroxylase activity
(~1–3 mM) (14).
Hypoxia-inducible factor-1 is particularly relevant to colorectal
cancer, with HIF-1α expression being identified as an independent
indicator of poor prognosis in a large prospective study of 731
patients (3). In addition, whereas HIF-1α alone was not signifi-
cant, in combination with two of its target gene products (CXCR4
and VEGF) it was associated with distant metastasis and poor
disease-free survival (49). In another study, high VEGF expression
was also found to be associated with poor survival, whereas HIF-
1α was borderline significant (50). These studies also highlight the
dual control of the HIF-1 transcriptional response by the PHDs
and FIH and the importance of measuring HIF-1α protein lev-
els and its downstream gene products in combination, as we have
done here. That both VEGF and BNIP3, but not HIF-1α, protein
levels were inversely correlated to the tumor ascorbate content
agrees with the observation that FIH may be more dependent on
ascorbate for activity than the PHDs (12). Thus, ascorbate may
have a greater influence on curbing HIF-1 transcriptional activity
than it does on protein stabilization of HIF-1α.
If ascorbate is to be considered as a potential cancer therapy,
there needs to be a clear understanding of its pharmacokinetics
and mechanism of action in tumor tissue before appropriately
designed clinical trials begin. Ascorbate may be active only in par-
ticular tumor types that are HIF-dependent or have a supportive
microenvironment. Moreover, the dosing regimen needs to be clar-
ified in order to achieve effective tumor tissue ascorbate levels. As
there is considerable skepticism regarding the usefulness of ascor-
bate in treating cancer, addressing these important mechanistic
issues will shed light on previous clinical research and direct the
nature of future human studies.
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